SBIR Phase I: A New Vaccine Development Method

Award Information
Agency:
National Science Foundation
Branch
n/a
Amount:
$99,937.00
Award Year:
2006
Program:
SBIR
Phase:
Phase I
Contract:
0610716
Agency Tracking Number:
0610716
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
NovaSterilis
3109 North Triphammer, Lansing, NY, 14882
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Timothy Christensen
Dr
(607) 330-2772
twc1@novasterilis.com
Business Contact:
Timothy Christensen
Dr
(607) 330-2772
twc1@novasterilis.com
Research Institution:
n/a
Abstract
This Small Business Innovation Research (SBIR) Phase I research project aims to develop a novel method for the production of whole cell vaccines using the supercritical CO2 technology. The majority of current whole cell vaccine preparations are made using formalin inactivation which has numerous drawbacks including residual formaldehyde, denaturation of key antigens, and lack of sterility requiring preservatives. Supercritical CO2 inactivation of leaves no toxic residuals, does not denature proteins, and is inherently sterile. Commercially, the application is a production process for a higher quality vaccine which may require fewer doses as well as open the door to the quick and inexpensive manufacture of vaccines to emerging diseases for which current methodologies do not create useful vaccines, or where these methods are not cost-effective given a small financial return. In addition to the production of new vaccines the sterilization of existing subunit vaccines using this technology will reduce the need for preservatives and increase the safety of vaccine preparations. Both companies and the public health will benefit from safer, higher quality, and less expensive vaccine preparations.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government